Latest news with #AsmaIbrahimAlMannaei
Al Etihad
17-04-2025
- Health
- Al Etihad
DoH partners with Gilead Sciences to propel healthcare innovation, cell therapy advancement
17 Apr 2025 18:59 ABU DHABI (ALETIHAD)As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW).As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the the presence of Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said, 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences, commented, 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.'
Zawya
17-04-2025
- Health
- Zawya
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement
This collaboration supports Abu Dhabi's commitment to building a resilient healthcare ecosystem that prioritises preventative, personalised and comprehensive care Abu Dhabi, UAE: As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the emirate In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences. Reflecting Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for communities. This strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare practices. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences commented: 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our l contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.' ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@ About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017. About Kite Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.
Arabian Business
17-04-2025
- Health
- Arabian Business
Abu Dhabi inks MoU to build advanced life sciences labs in Masdar City
The Department of Health – Abu Dhabi (DoH) and the Abu Dhabi Investment Office (ADIO) have signed a Memorandum of Understanding (MoU) with Masdar City for the establishment of state-of-the-art health and life sciences laboratories to foster a thriving ecosystem for researchers and entrepreneurs. The agreement aims to support the development of infrastructure for laboratory spaces within Masdar City, equipped with advanced technologies to accommodate cutting-edge scientific investigation and fostering collaboration by developing programmes to attract top-tier researchers and start-ups. Abu Dhabi's health vision It also envisages talent development by implementing training programmes and workshops, collaborating with universities to offer internship and research opportunities and translating research into economic value by developing partnerships with pharmaceutical and biotechnology companies to promote industry-sponsored research and clinical trials. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, said research and development is the key to driving innovation and sustainable development of the health and life sciences ecosystem. 'With partnerships such as these, we aim to strengthen our commitment towards creating a resilient ecosystem that will fuel the discovery of transformative care models and treatments,' Al Mannaei said. Dr. Fatma Al Mulla, Health, Endurance, Longevity and Medicine Cluster at ADIO, said the agreement signals Abu Dhabi's determination to shape the next frontier of life sciences. 'By building spaces that bring together researchers, entrepreneurs, and emerging technologies within our new 'Health, Endurance, Longevity, and Medicine (HELM)' cluster, we are cultivating an environment where scientific ambition can translate into practical breakthroughs,' Al Mulla said. Under the agreement, ADIO, in collaboration with DoH and Masdar City, will develop a strategic framework to assess the long-term impact of the health and life sciences laboratories on Abu Dhabi's economic and healthcare priorities. ADIO will also facilitate global investment partnerships to help deliver high-impact scientific breakthroughs, and will play a key role in exploring mechanisms to ensure that talent development initiatives contribute to workforce sustainability.
Al Etihad
16-04-2025
- Health
- Al Etihad
Abu Dhabi to establish state-of-the-art health and life sciences laboratories as part of its Health, Endurance, Longevity, and Medicine (HELM) cluster
16 Apr 2025 20:27 ABU DHABI (ALETIHAD) The Department of Health – Abu Dhabi (DoH) and Abu Dhabi Investment Office (ADIO) have partnered with Masdar City to establish state-of-the-art health and life sciences laboratories in order to foster a thriving ecosystem for researchers and entrepreneurs in the emirate. The partnership was signed as part of Abu Dhabi's recently launched Health, Endurance, Longevity, and Medicine (HELM) cluster at Abu Dhabi Global Health Week 2025 (ADGHW), being held at ADNEC Centre Abu Dhabi until April 17, 2025. In the presence of Dr Noura Khamis Al Ghaithi, Undersecretary of DoH, the agreement was signed by Dr Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, Dr Fatma Al Mulla, Head of the HELM Cluster at ADIO, and Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar agreement covers a number of key pillars, including the development of laboratory spaces within Masdar City that are equipped with advanced technologies to accommodate cutting-edge scientific investigation, and the development of collaborative programmes to attract top-tier researchers and start-ups. The agreement will also seek to establish partnerships with academic institutions and industry leaders with the aim of promoting knowledge exchange and collaborative research projects, as well as to create incubator and accelerator programmes that support the growth of life-science start-ups. In addition, talent development will be a key pillar under the agreement, with a focus on implementing training programmes and workshops in collaboration with universities that offer internship and research opportunities for students, and institutions that organise regular scientific symposia and conferences to showcase research outcomes and attract international expertise. The agreement will also emphasise the translation of research into economic value through the development of partnerships with pharmaceutical and biotechnology companies, promoting industry-sponsored research and clinical trials by means of a framework that measures and enhances the economic impact of the laboratories on Abu Dhabi's health and life sciences sector. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi, said: 'Research and development is the key to driving innovation and sustainable development of the health and life sciences ecosystem, which in turn promotes proactive, holistic care of our communities. With partnerships such as these, we aim to strengthen our commitment towards creating a resilient ecosystem that will fuel the discovery of transformative care models and treatments. This initiative reinforces Abu Dhabi's mission to accelerate the future of healthcare not only for the UAE but for the global community.'Dr. Fatma Al Mulla, Head of the HELM Cluster at ADIO, said: 'This agreement signals Abu Dhabi's determination to shape the next frontier of life sciences. By building spaces that bring together researchers, entrepreneurs, and emerging technologies within our new HELM Cluster, we are cultivating an environment where scientific ambition can translate into practical breakthroughs. It's a step toward redefining how innovation contributes to health outcomes, global competitiveness and Abu Dhabi's long-term prosperity.'Under the agreement, ADIO, in collaboration with DoH and Masdar City, will develop a strategic framework to assess the long-term impact of the health and life sciences laboratories on Abu Dhabi's economic and healthcare priorities, reinforcing the emirate's position as a global research and innovation hub. ADIO will also facilitate global investment partnerships to help deliver high-impact scientific breakthroughs, and will play a key role in exploring mechanisms to ensure that talent development initiatives contribute to workforce Al Breiki, Executive Director of Sustainable Development at Masdar City, said: 'This agreement reinforces Masdar City's role as a cornerstone in Abu Dhabi's mission to become a global hub for life sciences and innovation. As home to a growing cluster of biotechnology, genomics, and research-driven companies within our free zone, we offer a thriving ecosystem designed to support scientific advancement, cross-sector collaboration, and talent development. Through this partnership, we are building purpose-designed laboratory spaces that meet international sustainability standards and serve as launchpads for groundbreaking research. Together with our partners, we aim to translate science into scalable impact, contributing to Abu Dhabi's knowledge-based economy and the objectives of the Falcon Economy.'The strategic partnership between DoH, ADIO and Masdar City to establish labs that meet the international standards for safety, sustainability, and environmental responsibility in Abu Dhabi aligns with the 'Investment in life sciences: Driving global innovation forward' pillar of ADGHW. It aims to benefit the wider healthcare industry in the region, by fostering collaborations between researchers, entrepreneurs, investors and academicians to create future-ready frameworks for research and innovation. ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being'. It places a strong emphasis on community-driven health and wellbeing, with a proactive approach centred around preventive, personalised, and holistic care.
Zawya
16-04-2025
- Health
- Zawya
Department of Health Abu Dhabi, Abu Dhabi Investment Office and Masdar City sign a MoU
In an effort to enhance innovation, health services and world-class care for patients As part of the agreement, pioneering health and life sciences laboratories will be setup in Masdar City, the emirate's ground-breaking sustainable urban community The MoU was signed as part of Abu Dhabi's recently launched Health, Endurance, Longevity, and Medicine (HELM) clusterto reinforce Abu Dhabi's status as a global health and life sciences hub This partnership aims to further strengthen DoH's efforts to encourage a culture of research and innovation, driven by talent development, technological advancement and multi-regional partnerships Abu Dhabi, UAE: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, and the Abu Dhabi Investment Office (ADIO) have signed a Memorandum of Understanding (MoU) with Masdar City for the establishment of state-of-the-art health and life sciences laboratories to foster a thriving ecosystem for researchers and entrepreneurs. The MoU was signed as part of Abu Dhabi's recently launched Health, Endurance, Longevity, and Medicine (HELM) clusterat the Abu Dhabi Global Health Week 2025 (ADGHW), held at the Abu Dhabi National Exhibition Centre (ADNEC) between 15 – 17 April 2025. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), Dr. Fatma Al Mulla, Head of the Health, Endurance, Longevity and Medicine Cluster at ADIO at ADIO, and Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City. The MoU covers four key pillars namely, infrastructure development of laboratory spaces within Masdar City, equipped with advanced technologies to accommodate cutting-edge scientific investigation, fostering collaboration by developing programs to attract top-tier researchers and start-ups, establishing partnerships with academic institutions and industry leaders to promote knowledge exchange and collaborative research projects and creating incubator and accelerator programs to support the growth of life-science start-ups, talent development by implementing training programs and workshops, collaborating with universities to offer internship and research opportunities for students and organising regular scientific symposia and conferences to showcase research outcomes and attract international expertise, and translating research into economic value by developing partnerships with pharmaceutical and biotechnology companies to promote industry-sponsored research and clinical trials and creating a framework to measure and enhance the economic impact of the laboratories on Abu Dhabi's health and life sciences sector. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi, said: 'Research and development is the key to driving innovation and sustainable development of the health and life sciences ecosystem, which in turn promotes proactive, holistic care of our communities. With partnerships such as these, we aim to strengthen our commitment towards creating a resilient ecosystem that will fuel the discovery of transformative care models and treatments. This initiative reinforces Abu Dhabi's mission to accelerate the future of healthcare not only for the UAE but for the global community.' Dr. Fatma Al Mulla, Health, Endurance, Longevity and Medicine Cluster at ADIO, said: 'This agreement signals Abu Dhabi's determination to shape the next frontier of life sciences. By building spaces that bring together researchers, entrepreneurs, and emerging technologies within our new Health, Endurance, Longevity, and Medicine (HELM) cluster, we are cultivating an environment where scientific ambition can translate into practical breakthroughs. It's a step toward redefining how innovation contributes to health outcomes, global competitiveness and Abu Dhabi's long-term prosperity.' Under the agreement, ADIO, in collaboration with DoH and Masdar City, will develop a strategic framework to assess the long-term impact of the health and life sciences laboratories on Abu Dhabi's economic and healthcare priorities, reinforcing the emirate's position as a global research and innovation hub. ADIO will also facilitate global investment partnerships to help deliver high-impact scientific breakthroughs, and will play a key role in exploring mechanisms to ensure that talent development initiatives contribute to workforce sustainability. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, said: 'This agreement reinforces Masdar City's role as a cornerstone in Abu Dhabi's mission to become a global hub for life sciences and innovation. As home to a growing cluster of biotechnology, genomics, and research-driven companies within our Free Zone, we offer a thriving ecosystem designed to support scientific advancement, cross-sector collaboration, and talent development. Through this partnership, we are building purpose-designed laboratory spaces that meet international sustainability standards and serve as launchpads for groundbreaking research. Together with our partners, we aim to translate science into scalable impact, contributing to Abu Dhabi's knowledge-based economy and the objectives of the Falcon Economy.' This strategic partnership between DoH, ADIO and Masdar City to establish labs that meet the international standards for safety, sustainability, and environmental responsibility in Abu Dhabi aligns with the 'Investment in life sciences: Driving global innovation forward' pillar of ADGHW. It aims to benefit the wider healthcare industry in the region, by fostering collaborations between researchers, entrepreneurs, investors and academicians, to create future-ready frameworks for research and innovation. ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@ +971 50 536 6660 About the Abu Dhabi Investment Office (ADIO): The Abu Dhabi Investment Office (ADIO) is the government vehicle responsible for accelerating Abu Dhabi's growth and enabling the emirate's economic transformation. Through comprehensive support services, ADIO enables both local and foreign investors to shape industries of the future set to transform liveability, technology, resources and value-added services. Initiatives focused on regional tourism and retail development, as well as public-private partnerships, ensure that community well-being is at the centre of Abu Dhabi's economic transformation. With a robust network of investors, strong collaboration with key stakeholders and a global presence, ADIO is committed to empowering those who invest with Abu Dhabi to make a lasting global impact. For more information, visit: For more information, please contact: ADIO@ +971 50 204 9791
